Navigation Links
Surveyed U.S. and European Neurologists Agree that a Therapy's Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Date:3/20/2013

BURLINGTON, Mass., March 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that a therapy's effect on physical disability is the most influential attribute when making prescribing decisions for secondary-progressive multiple sclerosis (SP-MS)*. These same neurologists cite a therapy's effect on quality of life as the second-most important attribute, ahead of an effect on relapses, imaging metrics and other functional domains.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Current management of SP-MS relies on the use of mainline disease-modifying therapies (which include interferon-betas and Teva's Copaxone), most of which are approved broadly for the treatment of relapsing forms of MS. This category encompasses relapsing-remitting MS (RR-MS) and SP-MS patients who continue to experience relapses. Interviewed thought leaders suggest that, based on data in RR-MS, Genzyme/Sanofi/Bayer HealthCare's Lemtrada may offer advantages over sales-leading Copaxone on measures of physical disability—potentially translating into clinical benefits for SP-MS patients. 

"The neurologists we surveyed indicate that an improved effect on physical disability is one of the greatest unmet needs in SP-MS," said Decision Resources Analyst Georgiana L. Kuhlmann , S.M. "Drawing on clinical data from RR-MS trials, interviewed thought leaders indicate that Lemtrada has demonstrated the potential to partially fulfill this unmet need."

According to the DecisionBase 2013 report entitled On What Attributes Will Neurologists and Payers Differentiate Novel Therapies for Secondary-Pro
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
4. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
5. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
6. Mylan Launches Generic Lipitor® in Five European Countries
7. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
8. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
9. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
10. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
11. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Decision Resources Group finds that the laparoscopic device market ... increase to a value of over $4.3 billion by ... the large direct energy device market. In particular, premium-priced ... to the advantages they offer and as new products ... Resources Group,s coverage of the U.S. laparoscopic device market: ...
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... , December 17, 2014 Revenue and ... expenditure on research and development In the past ... revenue by two percent to EUR 4.287 billion (last year: ... by 14 percent to EUR 360 million. "Overall, 2013/14 was ... Michael Kaschke , President and CEO of Carl Zeiss ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... with Leading Researchers having Clinical Experience with Antimicrobials ... April 22 NovaBay Pharmaceuticals, Inc. (NYSE Amex: ... developing first-in-class, potent, well-tolerated products to treat and ... chance of developing drug resistance, today announced an ...
... initiation of clinical studies; Data to be presented ... Drug discovery and development company Esperance Pharmaceuticals ... program that support the initiation of clinical ... from the Company,s Cationic Lytic Peptide (CLYP(TM)) platform ...
Cached Medicine Technology:NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 2NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 3NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 4First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 2First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 3
(Date:12/20/2014)... is a professional company offering many kinds of ... its new engineered bamboo flooring collection, and announced a ... BambooIndustry.com’s customers come from many countries in the world: ... CEO of the company, the global bamboo flooring market ... years, and the demand for eco-friendly bamboo flooring products ...
(Date:12/20/2014)... December 20, 2014 Weddingshe.com has recently ... launched a site-wide promotion of special occasion dresses for ... popular supplier of special occasion dresses for global women. ... with big discounts, up to 80% off. Among the ... Sequins Short Sweet 16 Dress) is very popular. What’s ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... ) that allege a metal-on-metal version of the ... move forward in state and federal courts, Bernstein ... in New Jersey’ Bergen County Superior Court on ... were permitted to begin deposition of plaintiffs on ...
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress wholesaler and ... for 2015. Great discounts are now offered on ... can get a discount, up to 80% off, when ... January 30, 2015. , VogueQueen.com has recently released its ... dress promotion. Many customers worldwide like VogueQueen’s special designs ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP ... suggests that children treated with the medication may ... to breast development and lactation. The study, which ... children and adolescents who began treatment with risperidone, ...
Breaking Medicine News(10 mins):Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... to be worst hit by the bird flu, have confirmed ... disease //in Shanxi province on Monday. ,The officials ... identified after an indefinite number of chickens died in poultry ... they have sent the samples of the dead birds to ...
... restrictions that are to be placed on advertising junk food ... games, cinemas, packaging, and school sponsorship. Reports also indicate that ... the use of loyalty cards in store, so that healthy ... contain high levels of salt, fat and sugar. ...
... to a report put forth on ... nursing education of Witwatersrand University, ... to suffer from anemia and elevated ... pregnancy and eventually deliver babies with ...
... new way of freezing human eggs which will be a blessing ... able to have children. , ,Women’s eggs are very delicate ... to sperms which can be easily frozen and thawed. ... researchers which hold promise over the present technique being used. ...
... for health in Andhra Pradesh, the state has recorded the highest ... rate is stuck at 62 per 1000 live births for the ... very slow rate and perhaps will take another decade to touch ... Pradesh back in the achievement of the millennium development goals targeted ...
... in Sydney have identified a cue to detect depth in motion. ... is dynamic //half-occlusion. This is helpful in achieving a perception of ... a free access on Association for Research in Vision and Ophthalmology ... established by Leonardo da Vinci, Drs.Kevin Brooks and Barbara Gillam of ...
Cached Medicine News:Health News:Junk Food Advertisements To Be Restricted In All Forms of Media 2
... Anchor is available in 3.5 mm, 5 mm ... minor diameter and a cancellous screw thread design ... laser mark on the distal part of the ... eyelets. When the anchor is inserted, the vertical ...
... - As easy to use as its ... demanding medical justification of therapeutic procedures. For ... tract symptoms (LUTS), that requires urodynamics. ... becoming routine in the office environment, with ...
... The FASTak II Suture Anchor is a ... that is inserted directly into bone without predrilling ... the Tear Drop Handle, Keyless Chuck or the ... and SLAP repairs as well as other small ...
... offer the best bioabsorbable solution for soft ... thread design and small core diameter provide ... braided suture loop is molded into the ... eyelet that virtually eliminates abrasion to attached ...
Medicine Products: